Human cd47 expression protects porcine cells from xenogeneic human macrophage phagocytosis

Kentaro Ide,Hui Wang,Toshimasa Asahara,Megan Sykes,Yong-Guang Yang,Hideki Ohdan

2006-01-01

Abstract:16 HUMAN CD47 EXPRESSION PROTECTS PORCINE CELLS FROM XENOGENEIC HUMAN MACROPHAGE PHAGOCYTOSIS THROUGH INHIBITORY CD47-SIRPα SIGNALING. Kentaro Ide, Hui Wang, Toshimasa Asahara, Megan Sykes, Yong-Guang Yang, Hideki Ohdan. Department of Surgery, Hiroshima University, Hiroshima, Japan; TBRC, Massachusetts General Hospital, Boston, MA. Background: We have previously reported that human macrophages(MΦ) can phagocytose porcine cells in the absence of antibody or complement opsonization, and that the removal of α1,3-galactosyl xenoantigens from the porcine cells failed to prevent the phagocytosis. A recent report indicates that the signal regulatory protein (SIRP)α is a critical immune inhibitory receptor on MΦ, and its interaction with CD47, a ligand for SIRPα, prevents autologous phagocytosis. Considering the limited compatibility (73%) in amino acid sequences between pig and human CD47, we hypothesized that the interspecies incompatibility of CD47 may contribute to the rejection of xenogeneic cells by MΦ. Methods: In order to determine whether pig CD47 can interact with human SIRPα, we compared the SIRPα tyrosine phosphorylation in human MΦ after contact with porcine and human RBCs. To further determine whether the expression of human CD47 on porcine cells could confer protection from phagocytosis by human MΦ, we generated human CD47-expressing porcine cell lines by transfecting the porcine B lymphoma-like cells (LCL) with a human CD47 expressing plasmid. The phagocytotic activities of human MΦ toward porcine LCL were evaluated by in vitro assays in the presence or absence of anti-porcine antibodies and complements. CFSElabeled human CD47-transfected LCL and control vector-transfected LCL were incubated with human peripheral and reticuloendothelial MΦ for 4 h in the presence or absence of human IFN-γ. Results: Western blotting revealed that the incubation of human MΦ with human RBCs resulted in significant SIRPα tyrosine phosphorylation. However, SIRPα tyrosine phosphorylation was not induced in human MΦ incubated with porcine RBCs, as observed in the case of MΦ in the control that were incubated with the medium alone. Human CD47 expression on porcine cells radically reduced the susceptibility of the cells to phagocytosis by human peripheral and reticuloendothelial MΦ, regardless of the presence or absence of antibody opsonization. Conclusions: These results indicate that the interspecies incompatibility of CD47 significantly contributes to the rejection of xenogeneic cells by MΦ. Genetic manipulation of porcine cells for expression of human CD47 may provide a novel approach in preventing macrophage-mediated xenograft rejection through inhibitory CD47-SIRPα signaling. Abstract# 17 DEVELOPMENT OF ANTI-PIG (ANTI-GAL AND ANTI-NONGAL) ANTIBODIES IN INFANT BABOONS AND HUMANS: IMPLICATIONS FOR XENOTRANSPLANTAION. PPM Rood, H Hara, H-C Tai, M Ezzelarab, J Busch, S Ball, D Ayares, RW Wolf, R Manji, L Bailey, DKC Cooper. Starzl Transplantation Institute, Pittsburgh, PA; Revivicor, Blacksburg, VA; UOHSC, Oklahoma City, OK; University of Alberta, Edmonton, Canada; Loma Linda University, CA. Background: Preformed antibodies (Ab) play a role in the rejection of wild-type (WT) and GT-KO pig xenografts. We studied the development of these Ab in the first year of life in humans and baboons. Methods: Sera from 56 baboons (age 6-70 weeks) and 42 humans (age 064 weeks) were tested by flow cytometry for binding of IgM and IgG to PBMC from WT and GT-KO pigs of blood group O. Complement-dependent cytotoxicity assays were also carried out (n=44), and 13 baboons have to date been tested for the presence of anti-A/B blood group Ab. Results: Infant Baboons: There was no or minimal IgM binding to WT PBMC seen in the first 10 weeks; the incidence and extent of binding steadily increased with age (p<0.05). No or minimal IgM binding to GT-KO PBMC was seen till 19 weeks; and the extent of binding remained low throughout the first year, with no correlation with age. Anti-A/B Ab were not detected before 19 weeks. Months 0-6: 93% of sera showed IgM binding to WT PBMC (with 78% cytotoxicity), compared to only 48% that showed (a low level of) binding to GT-KO PBMC (13% cytotoxicity). IgG binding was 41% (WT) and 0% (GT-KO). Months 7-12: IgM binding to WT was 100%, and to GT-KO was 61%; IgG binding was 57% and 4%, respectively. Infant Humans: Definite IgM binding to WT PBMC was seen in some as early as 1 week, and binding steadily increased with age (p<0.05). No or only minimal IgM binding to GT-KO PBMC was seen in the first 29 weeks; and the level of anti-nonGal Ab remained low throughout the first year, with no correlation with age. Months 0-6: 63% of sera showed IgM binding to WT PBMC, compared to 38% that showed (a low level of) binding to GT-KO PBMC. IgG binding was 81% (WT) and 31% (GT-KO), but most of this in the first months was probably maternal Ab. Months 7-12: IgM binding to WT was 100%, and to GT-KO was 85%; IgG binding was 100% and 77%, respectively. Conclusions: (1) In both baboons and humans, anti-Gal Ab develop during the first 3 months, and steadily increase during the fist year. Anti-nonGal Ab develop later, and remain at a minimal level throughout the first year. (2) GT-KO organ or cell transplants could possibly be carried out in early infancy in the relative absence of anti-nonGal Ab.